Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2025)

Cellebrite DI (CLBT) has reported Cash & Equivalents for 6 consecutive years, with $124.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 35.06% year-over-year to $124.5 million; the TTM figure through Dec 2025 stood at $124.5 million (down 35.06% YoY), while the FY2025 annual figure was $124.5 million, down 35.06% from the prior year.
• Cash & Equivalents came in at $124.5 million for Q4 2025 at Cellebrite DI, down from $281.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $281.4 million in Q3 2025, with the low at $84.6 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $134.1 million, with a median of $123.4 million recorded in 2024.
• Across the five-year window, Cash & Equivalents plunged 39.96% in 2022 and soared 116.23% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $146.0 million in 2021, then plunged by 39.96% to $87.6 million in 2022, then jumped by 116.23% to $189.5 million in 2023, then advanced by 1.13% to $191.7 million in 2024, then slumped by 35.06% to $124.5 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $124.5 million, $281.4 million, and $179.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.